Health News

Doctors agree that vitamin D promotes bone health, but a belief that it can also prevent cancer, cardiovascular disease and other causes of death has been a major health controversy. Consistent with advice issued last fall by the Institute of Medicine, a new study finds that vitamin D did not confer benefits against mortality in postmenopausal women after controlling for key health factors such as abdominal obesity.

Read more

Filed under: Pharmacy News
Tags: cancer, medicine, Pharmacy

Related posts

• Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma [...]
  
  
• When To Administer Food And Drugs Together (0)
  A regulatory bias against taking oral anti-cancer medications with food places many patients at increased risk for an overdose and forces them to "flush costly medicines down the toilet," argues Mark Ratain, MD, an authority on cancer-drug dosing. In a commentary published early online Sept. 19 in the Journal of Clinical Oncology, Ratain, the Leon [...]
  
  
• What Is Herceptin (trastuzumab)? What Is Herceptin For? (0)
  Herceptin is the brand name of a medicine called trastuzumab. This medicine can stop the growth of breast cancer and sometimes reduce the size of the tumor. Herceptin is given by a drip into a vein. It can be given in combination with chemotherapy, or on its own to patients who have already had [...]
  
  
• What Is Herceptin (trastuzumab)? What Is Herceptin For? (0)
  Herceptin is the brand name of a medicine called trastuzumab. This medicine can stop the growth of breast cancer and sometimes reduce the size of the tumor. Herceptin is given by a drip into a vein. It can be given in combination with chemotherapy, or on its own to patients who have already had [...]
  
  
• VisEn Medical launches two new agents for imaging quantification (0)
  VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand [...]